ArticleOncoimmunology2014
Vitamin B6 improves the immunogenicity of cisplatin-induced cell death.
Article in Oncoimmunology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 21 citations in OpenAlex.
- Dihydroartemisinin restores the immunogenicity and enhances the anticancer immunosurveillance of cisplatin by activating the PERK/eIF2α pathway.Cell & bioscience · 2024Article
- The Crosstalk between Gut Microbiota and Nervous System: A Bidirectional Interaction between Microorganisms and Metabolome.International journal of molecular sciences · 2023Review
- Science-Driven Nutritional Interventions for the Prevention and Treatment of Cancer.Cancer discovery · 2022Article
- MicroRNA339 Targeting PDXK Improves Motor Dysfunction and Promotes Neurite Growth in the Remote Cortex Subjected to Spinal Cord Transection.Frontiers in cell and developmental biology · 2020Article
- Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response.International journal of molecular sciences · 2018Review
- The function and mechanism of HMGB1 in lung cancer and its potential therapeutic implications.Oncology letters · 2018Review
- Autophagy, autophagy-associated adaptive immune responses and its role in hematologic malignancies.Oncotarget · 2017Review
- Autophagy-dependent danger signaling and adaptive immunity to poorly immunogenic tumors.Oncotarget · 2017Article
- Calreticulin expression: Interaction with the immune infiltrate and impact on survival in patients with ovarian and non-small cell lung cancer.Oncoimmunology · 2016Article
- Chemosensitization strategies for the treatment of lung cancer.Oncoscience · 2015Article
- Combinatorial strategies for the induction of immunogenic cell death.Frontiers in immunology · 2015Review
- Induction of Immunogenic Cell Death of Esophageal Squamous Cell Carcinoma by 5-Fluorouracil and Cisplatin.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We have recently demonstrated that pyridoxine, a precursor of vitamin B6, increases the immunogenicity of non-small cell lung carcinoma (NSCLC) cells succumbing to cisplatin (cis-diamminedichloroplatinum(II), CDDP). Accordingly, pyridoxine promoted the antineoplastic activity of CDDP in NSCLC-bearing mice only in the presence of an intact immune system. These findings may have implications for the development of novel strategies to circumvent CDDP resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.